Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 467,760 | 480,601 | 371,466 | 359,827 | 412,612 |
| Receivables | 366,221 | 345,538 | 214,131 | 235,246 | 264,926 |
| Inventories | 142,556 | 122,819 | 121,000 | 82,468 | 81,404 |
| Other current assets | 0 | 10,158 | 19,842 | 13,073 | 0 |
| TOTAL | $1,014,840 | $990,676 | $755,610 | $727,718 | $788,954 |
| Non-Current Assets | |||||
| PPE Net | 1,708 | 1,927 | 2,117 | 2,514 | 2,952 |
| Other Non-Current Assets | 58,709 | 66,120 | 63,663 | 77,053 | 93,145 |
| TOTAL | $60,417 | $68,047 | $65,780 | $79,567 | $96,097 |
| Total Assets | $1,075,257 | $1,058,723 | $821,390 | $807,285 | $885,051 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 93,662 | 93,581 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 56,798 | 38,602 | 54,241 | 55,287 | 38,572 |
| Accrued Expenses | 166,049 | 140,322 | 138,999 | 116,146 | 140,184 |
| TOTAL | $323,596 | $279,527 | $200,659 | $178,377 | $185,509 |
| Non-Current Liabilities | |||||
| Long Term Debt | 361,664 | 361,091 | 360,535 | 360,001 | 359,489 |
| Other Non-Current Liabilities | 19,850 | 16,937 | 103,891 | 104,691 | 111,514 |
| TOTAL | $381,514 | $378,028 | $464,426 | $464,692 | $471,003 |
| Total Liabilities | $705,110 | $657,555 | $665,085 | $643,069 | $656,512 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 127,830 | 126,525 | 126,290 | 125,682 | 125,516 |
| Common Shares | 12 | 12 | 12 | 12 | 12 |
| Retained earnings | -3,012,978 | -2,954,027 | -3,169,742 | -3,127,591 | -3,035,366 |
| Other shareholders' equity | -2,103 | -2,400 | -2,569 | -3,054 | -3,308 |
| TOTAL | $370,147 | $401,168 | $156,305 | $164,216 | $228,539 |
| Total Liabilities And Equity | $1,075,257 | $1,058,723 | $821,390 | $807,285 | $885,051 |